Guard Therapeutics International AB (publ) (GUARD.ST)
SEK 18.8
(2.73%)
SEK 18.8
(2.73%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -115.07 Million SEK | -0.13% |
| 2022 | -114.92 Million SEK | -40.32% |
| 2021 | -81.9 Million SEK | -103.34% |
| 2020 | -40.27 Million SEK | 9.05% |
| 2019 | -44.28 Million SEK | 48.54% |
| 2018 | -86.05 Million SEK | -27.52% |
| 2017 | -67.48 Million SEK | -23.99% |
| 2016 | -54.42 Million SEK | -81.45% |
| 2015 | -29.99 Million SEK | -408.53% |
| 2014 | -5.89 Million SEK | -29.0% |
| 2013 | -4.57 Million SEK | -114.15% |
| 2012 | -2.13 Million SEK | -126.65% |
| 2011 | -941.99 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -17.27 Million SEK | -11.0% |
| 2024 Q2 | -23.73 Million SEK | -37.4% |
| 2023 Q4 | -15.56 Million SEK | 36.34% |
| 2023 Q2 | -34.67 Million SEK | 14.62% |
| 2023 FY | -114.92 Million SEK | -0.0% |
| 2023 Q3 | -24.44 Million SEK | 29.5% |
| 2023 Q1 | -40.61 Million SEK | -2.08% |
| 2022 Q4 | -39.79 Million SEK | -16.6% |
| 2022 Q3 | -34.12 Million SEK | -56.12% |
| 2022 Q2 | -21.85 Million SEK | -14.17% |
| 2022 Q1 | -19.14 Million SEK | 15.15% |
| 2022 FY | -114.92 Million SEK | -40.32% |
| 2021 Q3 | -34.46 Million SEK | -197.06% |
| 2021 FY | -81.9 Million SEK | -103.34% |
| 2021 Q1 | -13.27 Million SEK | -34.2% |
| 2021 Q2 | -11.6 Million SEK | 12.59% |
| 2021 Q4 | -22.56 Million SEK | 34.52% |
| 2020 Q1 | -9.64 Million SEK | 20.51% |
| 2020 Q3 | -12.82 Million SEK | -47.14% |
| 2020 Q4 | -9.89 Million SEK | 22.88% |
| 2020 FY | -40.27 Million SEK | 9.05% |
| 2020 Q2 | -8.71 Million SEK | 9.62% |
| 2019 FY | -44.28 Million SEK | 48.54% |
| 2019 Q3 | -8.03 Million SEK | 27.15% |
| 2019 Q4 | -12.13 Million SEK | -51.01% |
| 2019 Q1 | -13.09 Million SEK | 67.35% |
| 2019 Q2 | -11.02 Million SEK | 15.75% |
| 2018 Q1 | -14.6 Million SEK | 2.71% |
| 2018 Q4 | -40.08 Million SEK | -141.6% |
| 2018 Q3 | -16.59 Million SEK | -12.37% |
| 2018 FY | -86.05 Million SEK | -27.52% |
| 2018 Q2 | -14.76 Million SEK | -1.08% |
| 2017 Q3 | -18.33 Million SEK | 0.58% |
| 2017 Q1 | -15.69 Million SEK | 27.58% |
| 2017 Q4 | -15.01 Million SEK | 18.1% |
| 2017 FY | -67.48 Million SEK | -23.99% |
| 2017 Q2 | -18.44 Million SEK | -17.52% |
| 2016 FY | -54.42 Million SEK | -81.45% |
| 2016 Q3 | -14.37 Million SEK | -22.17% |
| 2016 Q4 | -21.66 Million SEK | -50.7% |
| 2016 Q2 | -11.76 Million SEK | -78.1% |
| 2016 Q1 | -6.6 Million SEK | 33.77% |
| 2015 Q2 | -8.33 Million SEK | -182.93% |
| 2015 Q3 | -6.92 Million SEK | 16.9% |
| 2015 Q1 | -2.94 Million SEK | -101.3% |
| 2015 Q4 | -9.97 Million SEK | -43.99% |
| 2015 FY | -29.99 Million SEK | -408.53% |
| 2014 FY | -5.89 Million SEK | -29.0% |
| 2014 Q4 | -1.46 Million SEK | 14.44% |
| 2014 Q3 | -1.71 Million SEK | -5.62% |
| 2014 Q2 | -1.62 Million SEK | -47.01% |
| 2014 Q1 | -1.1 Million SEK | -24.66% |
| 2013 Q4 | -884 Thousand SEK | 26.03% |
| 2013 FY | -4.57 Million SEK | -114.15% |
| 2013 Q2 | -1.55 Million SEK | -64.82% |
| 2013 Q1 | -941 Thousand SEK | -450.29% |
| 2013 Q3 | -1.19 Million SEK | 22.95% |
| 2012 Q4 | -171 Thousand SEK | 69.84% |
| 2012 Q3 | -567 Thousand SEK | 32.98% |
| 2012 FY | -2.13 Million SEK | -126.65% |
| 2012 Q2 | -846 Thousand SEK | 0.0% |
| 2011 FY | -941.99 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 53.783% |
| Ziccum AB (publ) | -21.56 Million SEK | -433.734% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -601.622% |
| BioArctic AB (publ) | 252.64 Million SEK | 145.548% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -13518.107% |
| Mendus AB (publ) | -100.65 Million SEK | -14.33% |
| Genovis AB (publ.) | 54.22 Million SEK | 312.218% |
| Intervacc AB (publ) | -93.57 Million SEK | -22.969% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -641.832% |
| Active Biotech AB (publ) | -46.48 Million SEK | -147.554% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 738.975% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -107.649% |
| Aptahem AB (publ) | -10.1 Million SEK | -1038.8% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 64.208% |
| Kancera AB (publ) | -65.04 Million SEK | -76.921% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 14.518% |
| Fluicell AB (publ) | -26.87 Million SEK | -328.115% |
| Saniona AB (publ) | -81.06 Million SEK | -41.952% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -830.183% |
| Biovica International AB (publ) | -126.07 Million SEK | 8.725% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -170.728% |
| AcouSort AB (publ) | -17.48 Million SEK | -558.049% |
| Xintela AB (publ) | -57.23 Million SEK | -101.043% |
| Abliva AB (publ) | -96.54 Million SEK | -19.187% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 64.571% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -3183.11% |
| OncoZenge AB (publ) | -15.9 Million SEK | -623.639% |
| Amniotics AB (publ) | -29.07 Million SEK | -295.807% |
| 2cureX AB (publ) | -36.36 Million SEK | -216.456% |
| CombiGene AB (publ) | -36.3 Million SEK | -216.96% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -686.018% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 70.064% |
| Camurus AB (publ) | 532.35 Million SEK | 121.616% |
| Corline Biomedical AB | -1.78 Million SEK | -6335.85% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 36.341% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -176.067% |
| I-Tech AB | 24.43 Million SEK | 570.935% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 85.406% |
| Cyxone AB (publ) | -21.66 Million SEK | -431.245% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | -8.595% |
| Biosergen AB | -27.26 Million SEK | -322.054% |
| Cantargia AB (publ) | -290.01 Million SEK | 60.322% |
| NextCell Pharma AB | -43.17 Million SEK | -166.545% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 36.341% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -573.088% |
| Nanologica AB (publ) | -69.96 Million SEK | -64.477% |
| SynAct Pharma AB | -224.49 Million SEK | 48.742% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -160.488% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -380.386% |
| LIDDS AB (publ) | -40.67 Million SEK | -182.915% |
| Lipum AB (publ) | -37.25 Million SEK | -208.888% |
| BioInvent International AB (publ) | -369.94 Million SEK | 68.894% |
| Alzinova AB (publ) | -16.52 Million SEK | -596.484% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 54.597% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -1699.914% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -471.394% |
| Simris Alg AB (publ) | -36.63 Million SEK | -214.107% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 21.488% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 62.931% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | -3.75% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -894.925% |